



SCIENTIFIC PROGRAM

DAY 1 Thursday, Dec 5th

| | OPENING CEREMONY** Chairpersons: Paolo A. Ascierto, Franco Marincola |
|---------|---|
| 6.20 pm | Update in Pathology Janis Taube |
| 6.40 pm | Update in Melanoma research Omid Hamid |
| 7.00 pm | Melanoma research funding opportunities Marc Hurlbert |
| 7.10 pm | Through the Keyhole: The Next Wave of Therapies for Patients with Uveal Melanoma, Kevin O´Neill and Marlana Orloff |
| 7.25 pm | Patient Advocacy reloaded. How to help patient empowerment in the new Melanoma era Samantha Guild and Claudia Piazza Cidonio |



SCIENTIFIC PROGRAM

DAY 2 Friday, Dec 6th

| 9.20 am | Introduction and objectives Paolo A. Ascierto |
|----------|--|
| | SESSION 1 MORE TRANSLATIONAL RESEARCH IN MELANOMA Chairpersons: Magdalena Thurin, Lisa Villabona |
| 9.30 am | What should you do with pathologic non-responders for neoadjuvant therapy? Christian Blank |
| 9.45 am | What do we know about how much neoadjuvant treatment to give? Michael Postow |
| 10.00 am | The an-unanswered questions in melanoma Iman Osman |
| 10.15 am | The latest omics tools for translational research questions Mitch Levesque |
| 10.30 am | Prognostic effects of combined clinicopathological factors and tumor mutation burden - an InterMEL study of Stage II/III primary cutaneous Marc S. Ernstoff |
| 10.45 am | DISCUSSION Round Table |
| 11.15 am | Coffee Break** |
| 11.30 am | CME SYMPOSIUM Neoadjuvant treatment in melanoma: an update Christian Blank |
| | The status of art of adjuvant therapy in melanoma Paolo A. Ascierto |
| | GREAT DEBATE Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov, Alessandro Testori |
| 12.20 am | Genetically modified cells therapy VS unmodified cells therapy Chrystal Paulos vs Allison Betof Warner |
| 12.45 am | Are IrAE associated with better outcomes? Yes or no Ryan Sullivan vs Olivier Michielin |
| 1.10 pm | Lunch** |
| | |



SCIENTIFIC PROGRAM

DAY 2 Friday, Dec 6th

| | SESSION 2 MELANOMA TUMOR BIOLOGY Chairperson: Paul Nathan |
|---------|---|
| 2.00 pm | Cancer Stem Cells and Lineage Plasticity as Immuno-therapeutic targets Dean Tang |
| 2.15 pm | Melanoma biology in the context of clinical and experimental resistance Roger Lo |
| 2.30 pm | New immunotherapy strategies based on understanding resistance Thomas Gajewski |
| 2.45 pm | Improving mRNA vaccine in melanoma Michelle Krogsgaard |
| 3.00 pm | The genetic and transcriptomic peripheral biomarkers of efficacy and toxicity to melanoma immune checkpoint inhibition Tomas Kirchhoff |
| 3.15 pm | Designing tumor-selective therapeutic strategies for RAS pathway-driven cancers Poulikos Poulikakos |
| 3.30 pm | DISCUSSION Round Table |
| 4.00 pm | SYMPOSIUM The new era of target therapy in metastatic melanoma Paolo A. Ascierto, Reinhard Dummer |
| 4.50 pm | SHORT SYMPOSIUM Current treatment of metastatic uveal melanoma and future prospectives Jessica C. Hassel |
| | GREAT DEBATE Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov |
| 5.20 pm | <u>Overview</u> Artificial intelligence-driven diagnosis of melanoma and melanoma skin cancers Titus Brinker |
| 5.35 pm | <u>Debates</u> Artificial intelligence VS human dermatology Gerardo Cazzato <i>vs</i> Laura Ferris |
| 6.00 pm | Artificial intelligence VS human pathology Carlo Bifulco <i>vs</i> Janis Taube |
| 6.25 pm | Artificial intelligence VS RWE Giuseppe Masucci <i>vs</i> Dirk Schadendorf |
| | ** Not included in the CME accredited program |